Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population‐based Study

@article{Yang2007RiskOE,
  title={Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population‐based Study},
  author={S. Yang and Y-H Kao Yang and M. Chong and Y. Yang and W-H Chang and C-S Lai},
  journal={Clinical Pharmacology & Therapeutics},
  year={2007},
  volume={81}
}
  • S. Yang, Y-H Kao Yang, +3 authors C-S Lai
  • Published 2007
  • Medicine
  • Clinical Pharmacology & Therapeutics
  • To compare the prevalence of extrapyramidal syndrome (EPS) between the first‐generation antipsychotics (FGAs) and second‐generation antipsychotics (SGAs), the co‐prescribing rate of anti‐Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5‐year study period. Among the SGAs, quetiapine had the lowest crude co‐prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the… CONTINUE READING
    41 Citations
    Olanzapine: review of safety 2008
    • 29
    Drug-Induced Parkinsonism in the Elderly
    • 66
    Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
    • 86
    • PDF
    Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
    • 11
    • PDF
    Parkinsonism following neuroleptic exposure: A double‐hit hypothesis?
    • 33
    Zotepine: a clinical review
    • 6

    References

    SHOWING 1-10 OF 83 REFERENCES
    Effects of Newer Antipsychotics on Extrapyramidal Function
    • 254
    Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy
    • G. Tognoni
    • Medicine
    • European Journal of Clinical Pharmacology
    • 1999
    • 51
    Extrapyramidal Symptoms with Atypical Antipsychotics
    • 152
    • PDF
    Pharmaco-epidemiology in 136 hospitalized schizophrenic patients.
    • 38
    Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.
    • 109
    Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.
    • 260
    Efficacy of newer generation antipsychotics in the treatment of schizophrenia
    • 130